Because the patent law change for Capoten
and 108 other drugs would transfer enormous costs to government health programs, drug consumers will essentially pay twice: once at the pharmacy and again as taxpayers.
The United States has eight of the top-ten best sellers, including Capoten
, Mevacor, and Ceclor.
pharmaceutical sales should be strong, led by Pravachol, Taxol, Glucophage and Monopril, whose gains should more than offset a sharp decline in Capoten
Although patent protection on the company's Capoten
, a cardiovascular medication, recently expired, there are other promising products in the pipeline.
Over a dozen companies have entered the market with generic versions of Capoten
The following drugs were included and are listed in the order of appearance in the journals and on the questionnaire: Voltaren, Wellbutrin, Prozac, Isoptin SR, PediaProfen, Feldene, Verelan, Capoten
, Carafate, Axid, Halcion, Cipro, Calan SR, Lorelco, Procardia XL, Cardizem, Tagamet, Suprax, Kerlone, and Ventolin.
Enalapril, a copy of Merck's Vasotec, and captopril, the equivalent of Bristol-Myers Squibb's Capoten
, are other generics currently available.
According to the terms of GATT, patent protection for Capoten
was extended from August 8, 1995 to February 13, 1996.
(captopril) would receive additional patent life, but its Pravachol (pravastatin sodium) would lose the additional protection.
, the company's best-selling cardiovascular drug - which was to lose patent protection in August - got a 16-month patent extension as a result of GATT.
And that includes any pending generic versions of Zantac [ranitidine HCl] and Capoten
(captopril), its best-selling cardiovascular drug, loses patent protection in 1995.